Iradimed Corp Proposes Offering Of Common Shares

IRADIMED CORPORATION (the "Company") IRMD, the only known provider of non-magnetic intravenous ("IV") infusion pump systems that are designed to be safe for use during magnetic resonance imaging ("MRI") procedures, today announced that Roger Susi, the President and Chief Executive of the Company (the "Selling Shareholder") intends to offer for sale in an underwritten secondary offering of shares of his common stock of the Company. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Roth Capital Partners is acting as the sole manager for the offering. The Company will not receive any proceeds from the offering. The shares described above are being offered by the Selling Stockholder pursuant to the Company's shelf registration statement filed with the Securities and Exchange Commission ("SEC"). This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the preliminary prospectus supplement and accompanying base prospectus relating to this offering may be obtained from Roth Capital Partners, 888 San Clemente, Newport Beach, CA 92660, (800) 678-9147 or by accessing the SEC's website, www.sec.gov.